InvestorsHub Logo
Followers 59
Posts 4696
Boards Moderated 0
Alias Born 04/27/2009

Re: None

Sunday, 04/11/2021 12:29:55 AM

Sunday, April 11, 2021 12:29:55 AM

Post# of 118379
What this means to our small molecule drug development programs is CBD appears when used with other compounds to amplify the desired outcome. Our current pipeline of NR2F6 small molecules both augment and inhibit interleukin-17 production, we see potential synergy between today's disclosed data and our ongoing small molecule programs."

https://www.gurufocus.com/news/956445/regen-biopharma-successfully-treats-rheumatoid-arthritis-using-cannabidiol-cbd-based-immune-modulatory-treatments